Q2 Earnings Estimate for NTLA Issued By William Blair

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at William Blair issued their Q2 2026 EPS estimates for Intellia Therapeutics in a research note issued to investors on Wednesday, March 26th. William Blair analyst M. Minter expects that the company will post earnings per share of ($1.22) for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

Several other equities analysts have also issued reports on the company. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research report on Monday, March 3rd. Barclays dropped their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $56.00 to $11.00 in a research report on Monday, January 27th. Citigroup upped their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Stock Down 3.9 %

NTLA stock opened at $8.07 on Friday. The business has a 50 day moving average of $9.98 and a 200 day moving average of $13.81. The firm has a market cap of $835.38 million, a PE ratio of -1.48 and a beta of 1.97. Intellia Therapeutics has a twelve month low of $8.03 and a twelve month high of $28.18.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 29,000 shares of company stock worth $352,551. Corporate insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter valued at about $25,000. Sterling Capital Management LLC increased its position in shares of Intellia Therapeutics by 866.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after purchasing an additional 2,867 shares during the last quarter. Whipplewood Advisors LLC purchased a new stake in Intellia Therapeutics during the 4th quarter valued at $40,000. Resona Asset Management Co. Ltd. bought a new stake in Intellia Therapeutics in the fourth quarter worth $43,000. Finally, Jones Financial Companies Lllp lifted its position in Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after buying an additional 2,280 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.